– Phase 2 open-label CONNECT1-EDO51 study open in Canada – – Potentially registrational, randomized, double-blind, placebo-controlled Phase 2 CONNECT2-EDO51 multinational…
AssureCare’s latest product, OptimAIzer, delivers on efficiency, efficacy, and satisfaction for payors, providers, and patientsCINCINNATI, Aug. 08, 2023 (GLOBE NEWSWIRE)…
Topline data expected as early as Q1 2024OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:…
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer…
WOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing…
First-ever set of professional guidelines informed by clinical research and expert consensus will set benchmarks for practitioners in an emerging…
Approximately 1.4 million Canadian women have PCOS, and this unique soft-gel capsule is approved to help them manage their symptoms…
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline of innovative gamma-delta T cell…
TAMPA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Healthmap Solutions, Inc. (Healthmap), an NCQA-accredited Kidney Population Health Management company, announced…
SBS-518 is a dual sigma receptor antagonist/dopamine active transporter inhibitor in development for the treatment of stimulant use disorder (e.g.,…